PODCAST

Oncology and Hematology

ReachMD

science & medicine medicine

All Episodes

00:00:00

Chairperson Perspective: Improving HR+/HER2- Breast...

Oncology and Hematology ·

2025/04/18

Host: Aditya Bardia, MD, MPH The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews

00:00:00

Targeting CD123 in AML: The Latest Therapeutic...

Oncology and Hematology ·

2025/04/11

Host: Jennifer Caudle, DO Guest: Naval Daver, MD Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it’s also associated with more proliferative disease that’s resistant to standard therapies. Given its prevalence and potential implications, a number of different CD123-targeting approaches are under investigation, including antibody-drug conjugates, bi-specific antibodies, fusion protein, and CAR T-cell therapy. In

00:00:00

Frontline Consolidation in B-ALL: Expert Insights on...

Oncology and Hematology ·

2025/04/08

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Aaron Logan, MD, PhD Although acute lymphoblastic leukemia (ALL) is a relatively rare disease with fewer than 7,000 people diagnosed each year in the US,1,2 there’s been a lot of progress in the management of B-cell ALL over the years. One key development comes from the E1910 Phase III trial, which explored the addition of blinatumomab to frontline consolidation chemotherapy for patients with Philadelphia chromosome-negative B-lineage

00:00:00

Advancing Cancer Care: Key Considerations for...

Oncology and Hematology ·

2025/04/07

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield,

00:00:00

ICI Combination Regimens for First-Line Treatment of...

Oncology and Hematology ·

2025/03/31

Host: Harry Yoon, MD Host: Jaffer Ajani, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform

00:00:00

Mutational Testing in mCRC: Methods and Data Driving...

Oncology and Hematology ·

2025/03/31

Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

00:00:00

Proactive Adverse Effect Management in mCRC:...

Oncology and Hematology ·

2025/03/31

00:00:00

The Impact of First-Line Treatment on Subsequent...

Oncology and Hematology ·

2025/03/31

00:00:00

From Guidelines to Practice: First-Line Treatment...

Oncology and Hematology ·

2025/03/31

00:00:00

Tailoring First-Line Regimens: Patient-Centric...

Oncology and Hematology ·

2025/03/31

00:00:00

Defining the Standard of Care and Optimal Sequencing...

Oncology and Hematology ·

2025/03/31

00:00:00

Strategies for Navigating First-Line Treatment...

Oncology and Hematology ·

2025/03/31

00:00:00

Navigating a Positive MCED Test and Negative...

Oncology and Hematology ·

2025/03/28

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test

00:00:00

Screening Modalities for Colon Cancer: What You Need...

Oncology and Hematology ·

2025/03/26

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods

00:00:00

Melanoma Treatment Breakthroughs: Improving Long-Term...

Oncology and Hematology ·

2025/03/17

Guest: Vernon K. Sondak, MD Melanoma treatment has undergone a rapid evolution. Immunotherapy has doubled survival rates, and timing the use of these drugs around surgery has shown to be even more effective. Dr. Vernon Sondak explores how the fight against melanoma is stronger than ever with new therapeutic combinations and evolving treatment strategies. Dr. Sondak is the Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa,

00:00:00

Evaluating First-Line Therapy for Acute...

Oncology and Hematology ·

2025/03/04

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yi Bin Chen, MD Guest: Olaf Penack, MD For the past several decades, standard treatment for acute graft-versus-host disease (aGVHD) has been systemic high-dose steroids.1 While essential in some ways to initially control aGVHD, steroids are not beneficial in the long run due to the immunosuppression and toxicities associated with high cumulative doses.1,2 So what can be done moving forward to improve first-line steroid response

00:00:00

Advancing Multidisciplinary Care in TGCT: Integrating...

Oncology and Hematology ·

2025/02/28

Host: William D. Tap, MD Host: John Healey, MD In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions

00:00:00

Exploring New and Emerging Treatments in Muscle...

Oncology and Hematology ·

2025/02/21

Host: Elizabeth R. Plimack, MD, MS, FASCO New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse

00:00:00

Patient Perspectives on Bladder Cancer

Oncology and Hematology ·

2025/02/21

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Lillibeth Velasco, MSN, RN New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique,

00:00:00

Reviewing the Latest Bladder Cancer Practice Guidelines

Oncology and Hematology ·

2025/02/21

227 results

Oncology and Hematology

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe